B. Metzler seel. Sohn & Co. AG Grows Position in Stryker Corporation $SYK

B. Metzler seel. Sohn & Co. AG grew its holdings in Stryker Corporation (NYSE:SYK) by 121.3% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 175,636 shares of the medical technology company’s stock after buying an additional 96,281 shares during the period. B. Metzler seel. Sohn & Co. AG’s holdings in Stryker were worth $55,297,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Sankala Group LLC purchased a new position in Stryker in the 4th quarter worth approximately $26,000. Godfrey Financial Associates Inc. purchased a new stake in shares of Stryker in the fourth quarter valued at approximately $26,000. United Financial Planning Group LLC acquired a new stake in shares of Stryker in the third quarter valued at approximately $27,000. Atlas Capital Advisors Inc. acquired a new stake in shares of Stryker in the fourth quarter valued at approximately $27,000. Finally, Gables Capital Management Inc. purchased a new position in Stryker during the second quarter worth approximately $25,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 50,000 shares of the stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total value of $17,005,000.00. Following the sale, the director directly owned 2,251,375 shares of the company’s stock, valued at approximately $765,692,637.50. This represents a 2.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 665,370 shares of company stock valued at $216,238,501. 4.60% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts have weighed in on SYK shares. Evercore set a $350.00 target price on shares of Stryker in a research note on Monday, July 6th. UBS Group assumed coverage on Stryker in a report on Tuesday, July 28th. They set a “buy” rating and a $400.00 target price for the company. Truist Financial lifted their target price on Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a research report on Friday, July 31st. Piper Sandler reduced their price target on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. Finally, Sanford C. Bernstein set a $410.00 target price on shares of Stryker in a research note on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and an average price target of $386.28.

Stryker Stock Up 1.0%

SYK stock traded up $3.39 during midday trading on Friday, reaching $331.09. 1,448,865 shares of the company were exchanged, compared to its average volume of 2,362,085. The company has a market cap of $127.00 billion, a price-to-earnings ratio of 34.31, a price-to-earnings-growth ratio of 2.17 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $396.86. The stock’s 50-day simple moving average is $326.64 and its 200 day simple moving average is $332.66.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. During the same period in the previous year, the business earned $3.13 EPS. The business’s quarterly revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s dividend payout ratio is currently 36.48%.

Trending Headlines about Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Wall Street remains broadly constructive on Stryker. Analysts maintain a consensus “Moderate Buy” rating and an average price target of $386.28, implying meaningful upside from recent levels. Although several firms lowered their targets, most retained Buy or Outperform ratings. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Positive Sentiment: Stryker’s latest quarterly results exceeded expectations: adjusted earnings were $3.69 per share versus a $3.49 consensus estimate, while revenue reached $6.59 billion against expectations of $6.58 billion. Revenue grew 9.4% year over year, and management maintained fiscal 2026 earnings guidance of $14.95–$15.10 per share.
• Positive Sentiment: Institutional ownership remains substantial at 77.09%, with major investors including Norges Bank, Bank of America and Legal & General recently establishing or expanding positions. This may help support the stock over the longer term.
• Neutral Sentiment: The company declared a quarterly dividend of $0.88 per share, equivalent to $3.52 annually and a yield of approximately 1.1%. The payout provides income support but is unlikely to be a major near-term catalyst.
• Negative Sentiment: Director Ronda Stryker sold 300,000 shares for approximately $100.8 million on August 18 and another 50,000 shares for approximately $17.0 million on August 19. The transactions reduced her direct ownership, potentially raising concerns about insider confidence even though she still owns roughly 2.25 million shares. Stryker Director Sells 50,000 Shares of Stock
• Negative Sentiment: Recent commentary characterizes Stryker’s sell-off as a potentially better entry point but notes that the latest quarter was not flawless. In addition, several analysts have trimmed price targets, suggesting expectations have moderated despite the overall bullish rating.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.